CureVac NV (CureVac NV) Total Liabilities : $295.87 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Total Liabilities?

CureVac NV's Total Liabilities for the quarter that ended in Dec. 2023 was $295.87 Mil.

CureVac NV's quarterly Total Liabilities declined from Jun. 2023 ($271.33 Mil) to Sep. 2023 ($256.46 Mil) but then increased from Sep. 2023 ($256.46 Mil) to Dec. 2023 ($295.87 Mil).

CureVac NV's annual Total Liabilities declined from Dec. 2021 ($530.81 Mil) to Dec. 2022 ($346.63 Mil) and declined from Dec. 2022 ($346.63 Mil) to Dec. 2023 ($295.87 Mil).

CureVac NV Total Liabilities Historical Data

The historical data trend for CureVac NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Total Liabilities Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

192.69

973.25

530.81

346.63

295.87

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															346.63	278.67	271.33	256.46	295.87

CureVac NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CureVac NV's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	203.26	+	(40.152	+	-0.00099999999998346
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	52.454	+	0)
	=	295.87

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	859.595	-	563.731
	=	295.86

CureVac NV's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	203.26	+	(40.152	+	-0.00099999999998346
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	52.454	+	0)
	=	295.87

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	859.595	-	563.731
	=	295.86

CureVac NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of CureVac NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.